EZZ receipts fall 37.67% to $7.15 million in Q1 FY27

Chinese E-commerce Weakness Cuts Quarterly Receipts

EZZ Life Science Holdings Limited (ASX:EZZ) is confronting a sharper sales problem than its cash-flow headline initially suggests. Customer receipts fell 37.67% year-on-year to $7.15 million in the September quarter, with the company attributing the decline to softer Chinese e-commerce demand, stronger competition and weaker-than-expected consumer spending.

The result extends a difficult pattern for the company’s China-facing channels, although the comparative period was also marked by a Q1 FY26 sales dip. EZZ said it is managing its exposure to those platforms while trying to widen its revenue base through Australian pharmacy, retail and international distribution.

Operating Cash Outflow Falls to $349,000

Against the weaker receipts, net cash used in operating activities narrowed to $349,000 from more than $3 million in the prior corresponding period. EZZ pointed to tighter working-capital management and cost control, with cash payments during the quarter including $3.64 million for manufacturing and operating costs, $2.56 million for advertising and marketing, and $904,000 in staff costs.

Cash and cash equivalents ended September at $9.16 million, down from $9.72 million at the end of June. The company remained debt-free excluding lease liabilities, and its Appendix 4C calculates approximately 26 quarters of funding based on the quarter’s operating cash outflow. That measure is mechanical rather than a forecast: future funding duration will depend on receipts, expenditure and trading conditions.

EAORON Growth Comes From a Modest Base

EAORON skincare sales rose 141.2% year-on-year, supported by airport billboard advertising, combined online and offline promotions and a Chemist Warehouse campaign. EZZ said the initiatives helped build sales momentum, but also acknowledged that EAORON’s absolute contribution remains modest relative to group revenue.

The company maintained a presence across close to 100 Australian and New Zealand pharmacy locations, including Direct Chemist Outlet and Priceline. It described the pharmacy channel as still being at an early stage, with the immediate focus on developing repeat sales rather than simply adding locations.

Distributor Receivables and Product Returns Remain Unresolved

The more immediate balance-sheet question sits with two distributors that owed EZZ a combined $3.86 million at quarter-end. The customers have cited Chinese regulatory and policy changes, difficult economic conditions in Asia and trouble selling products. EZZ had already recognised a $2.40 million allowance for potential credit loss in its FY26 annual report and is negotiating payment plans, debt recovery and possible stock returns.

The potential returns have an aggregate sales value of approximately $3.72 million, although the company has not determined whether they will occur or what value any returned stock could ultimately recover. EZZ said it would assess shelf life, quantities and resale opportunities if products are returned.

Xenitra Ramp-Up and Australian Open Spending Set the Next Test

Commercial activity under EZZ’s four-year exclusive global distribution agreement with Xenitra (ASX:XEN) remained modest, with less than $100,000 in sales recorded during the quarter. The arrangement includes minimum purchase commitments of $2.5 million a year, and EZZ said it expects Xenitra sales to begin ramping up from the December quarter. Its separate strategic cooperation framework with JD Health remains focused on brand awareness and positioning in China’s online healthcare market.

Management also expects operating cash outflows to begin stabilising from around March 2027, after the company’s Australian Open advertising commitment concludes at the end of January, subject to trading conditions and spending requirements. The next quarter should therefore show whether the improved cash discipline can persist while the company funds marketing, pursues distribution growth and works through the unresolved distributor exposures.